

Current State and Further Development of Animal Models of Serious Infections Caused by Acinetobacter baumannii and Pseudomonas aeruginosa—March 1, 2017

Speakers and Panelists

Thushi Amini, Ph.D.

Associate Director for Research
Office of Antimicrobial Products (OAP),
FDA, CDER

David Andes, M.D.

Professor, Departments of Medicine, Medical Microbiology and Immunology
Head, Division of Infectious Diseases
University of Wisconsin

Robert Bonomo, M.D.

Professor of Medicine, Pharmacology, Molecular Biology and Microbiology
Chief, Medical Service, Louis Stokes Cleveland Department of Veteran Affairs Medical Center
Case Western Reserve University

David Boucher, Ph.D.

Health Scientist Division of CBRN Countermeasures
Biomedical Advanced Research and Development Authority (BARDA)

Helen Boucher, M.D.

Director, Infectious Diseases Fellowship Program
Associate Professor of Medicine
Tufts University School of Medicine

Ed Cox, M.D., M.P.H.

Director, Office of Antimicrobial Products (OAP),
FDA, CDER

Binh Diep, Ph.D.

Associate Professor
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco

John Farley, M.D., M.P.H.

Deputy Director, Office of Antimicrobial Products (OAP),
FDA, CDER

Joanna Goldberg, Ph.D.

Professor, Department of Pediatrics, Division of Pulmonary, Allergy, Cystic Fibrosis and Sleep
Emory University

Tina Guina, Ph.D.

Program Officer

NIH/ National Institute of Allergy and Infectious Diseases (NIAID)

Judith Hewitt, Ph.D.

Chief, Biodefense Research Resources Section

NIH/NIAID

Julie Hutt, DVM, Ph.D., DACVP

Veterinary Pathologist

Lovelace Respiratory Research Institute

Robin Isaacs, M.D.

Chief Medical Officer

Entasis Therapeutics

Jane Knisely, Ph.D.

Program Officer

NIH/ NIAID

Matthew Lawrenz, Ph.D.

Associate Professor, Center for Predictive Medicine

Dept. of Microbiology and Immunology

University of Louisville School of Medicine

Gianluigi Li Bassi, M.D., Ph.D.

Researcher, Department of Pulmonary and Critical Care Medicine

University of Barcelona, Spain

Gabriel Meister, Ph.D.

Research Leader

Battelle Biomedical Research Center

Samuel Miller, M.D.

Professor of Medicine, Microbiology and Genome Sciences

University of Washington

Sumathi Nambiar, M.D., M.P.H.

Director, Division of Anti-infective Products

FDA

John Rex, M.D.

Chief Medical Officer and Director at F2G, Ltd.

Chief Strategy Officer at CARB-X - F2G, Ltd.

Andreas Wallnofer, Ph.D.
Interim Head of Development
Polyphor

Daniel Zurawski, Ph.D.
Senior Scientist, Principal Investigator, Division of Bacterial Diseases, Department of Wound Infections
Walter Reed Army Institute of Research (WRAIR)

Disclosures

Dr. Andes Research has received financial support from the grants and/or consulting: Astellas, Merck, GSK, Scynexis, Cubist, Forrest, Rempex, Dipexium, Nexcida, Durata, Actelion, Zavante, Paratek, Meiji, Geom, Cidara, Melinta, Theravance, Iterum, Sentinella, Kalidex, Novozymes, Trius, Taxis. Dr. Andes is also a member ABIM.

Dr. Helen Boucher serves on an NIH Adjudication Committee, Data Review Committees for Actelion and Medtronix, and as Treasurer of IDSA, Trustee of the Physicians of Tufts Medical Center, the American Board of Internal Medicine Infectious Diseases Board, and College of the Holy Cross.

Dr. Diep received research funding from NIH, Arsanis Biosciences, Cubist (now a part of Merck), Genentech (now a part of Roche), Integrated BioTherapeutics, MedImmune (now a part of AstraZeneca), and Pfizer.

Dr. Hutt is a full-time employee of Lovelace, which is a non-profit organization that performs regulated work for multiple commercial and government sponsors. The work presented herein was funded by NIAID. Dr. Hutt has no financial conflicts of interest.

Dr. Isaacs is a full time employee of Entasis Therapeutics.

Dr. Li Bassi has received funding from NIH, Hill-Rom, Bayer, Covidien, Ciel Medical, Theravance, Mediumimmune, Cubist, Cardeas Pharma, Lunguard, Biovo Technologies, and Toray, Ltd.

Dr. Meister is a full-time employee of Battelle, which is a non-profit organization that provides contracted research services to numerous government and commercial Sponsors. Dr. Meister has no financial conflicts of interest.

Dr. Miller serves on the scientific advisory board for Microbiome Insights.

Dr. Rex is Chief Medical Officer & Director, F2G, Ltd; Chief Strategy Officer, CARB-X; Non-Executive Director & Consultant, Adenium Biotech ApS; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific

advisory boards of Macrolide Pharmaceuticals; Spero Therapeutics; and Bugworks Research, Inc.; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Adenium Biotech ApS; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyphor, Ltd.; Heptares Therapeutics, Ltd.; and Gangagen, Ltd.

Dr. Wallnofer has the following disclosures: Partner at BioMed Partners, Basel, Switzerland, Founder of Wallnöfer Life Sciences Consulting Ltd. Consults Polyphor Ltd, Allschwil, Switzerland and acts *ad interim* as Head of Clinical Development. He has also served as the previous Head of Clinical Research & Exploratory Development at F. Hoffmann La Roche, Basel, Switzerland.